EMST 150 Training in Mild-Moderate OSA

November 10, 2026 updated by: Thomaz Fleury Curado, University Hospitals Cleveland Medical Center

Evaluating the Efficacy and Feasibility of Combined Expiratory Muscle Strength Training (EMST 150) and Oropharyngeal Myofunctional Therapy in Patients With Mild-to-Moderate Obstructive Sleep Apnea.

Obstructive Sleep Apnea is a condition in which the upper airway repeatedly becomes blocked during sleep, often due to weakness or collapse of the upper airway throat muscles. The purpose of this study is to evaluate whether combining a handheld breathing device (Expiratory Muscle Strength Training (EMST 150)) with structured, speech-language pathology-Guided mouth and throat exercises can help strengthen the muscles that keep the airway open, reduce snoring, and reduce sleep apnea severity while improving overall sleep quality. Participation in this study will last about 3 months. This includes a 5-week home breathing exercise program, two in-person clinic visits (at the beginning of the study and at Month 3), and two short phone check-ins.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44106
        • University Hospitals Cleveland Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of Mild-to-Moderate OSA (5<AHI<30 events/hour)
  • Patient willingness and physical capability to perform threshold-based respiratory exercises and daily oral myofunctional exercises.
  • Documented failure, intolerance (defined as regular use < 4 hours/night), or patient refusal of standard therapies, including Continuous Positive Airway Pressure (CPAP) and surgical interventions.

Exclusion Criteria:

  • Severe OSA (AHI>30 events/hour)
  • Active asthma, severe or poorly controlled asthma with low symptom perception, or severe chronic obstructive pulmonary disease (COPD)
  • Uncontrolled hypertension, defined as resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening, or any change in antihypertensive medication within the past 30 days, or significant cardiovascular disease.
  • Recent esophageal surgery, recent abdominal surgery, or presence of an abdominal hernia.
  • History of spontaneous pneumothorax, or incomplete recovery/healing following traumatic pneumothorax or rib fracture.
  • History of lung transplantation or lung resection.
  • Current tracheostomy or unhealed tracheostomy stoma.
  • Presence of a cerebrospinal fluid (CSF) drain or active intracranial pressure monitoring.
  • Active epistaxis (frequent/severe nosebleeds) or active hemoptysis within the past 30 days.
  • Tympanic membrane perforation (ruptured eardrum) or active inner/middle ear pathology.
  • Unrelated or uncontrolled gastroesophageal reflux disease (GERD).
  • Known or suspected pregnancy.
  • Active use of CPAP, mandibular advancement device (MAD), or hypoglossal nerve stimulation (HGNS) during the study period.
  • Any acute medical condition or clinical situation where generating intrathoracic, intro-abdominal, or intracranial pressure (similar to Valsalva maneuver) is clinically contraindicated.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participants with Obstructive Sleep Apnea (OSA)

Adult participants diagnosed with mild-to-moderate obstructive OSA.

Participants utilize the EMST 150 device to strengthen expiratory and upper airway musculature. During training, participants inhale deeply and exhale forcefully through the mouthpiece again calibrated resistance while maintaining an airtight lip seal to overcome the target threshold pressure.

Participants perform structured oral motor exercises :

  • Lingual maneuvers
  • Soft palate and velopharyngeal exercises
  • Facial and buccinator muscle conditioning to reinforce nasal breathing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, 3 months

The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that evaluates overall sleep quality and disturbances over a one-month time interval. With higher scores indicating poor sleep quality.

Baseline, 3 months
Change in Daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS)
Time Frame: Baseline, 3 months

The Epworth Sleepiness Scale (ESS) is a short, self-administered questionnaire used to measure a person's general level of daytime sleepiness and likelihood of dozing off in everyday situations. Scored on a scale from 0 would never doze, to 3 high chance of dozing.

Baseline, 3 months
Snore score as measured by smartphone application monitoring.
Time Frame: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Percentage of snoring sleep time as measured by smartphone application monitoring.
Time Frame: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Noise intensity in decibels as measured by smartphone application monitoring.
Time Frame: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Change in Isometric maximal tongue pressure (kPa) as measured by the Iowa Oral Performance Instrument (IOPI)
Time Frame: Baseline, 3 months

The Iowa Oral Performance Instrument (IOPI) is a portable, evidence-based medical device used to objectively measure, document, and train lip and tongue strength and endurance. The device digitally records maximum isometric pressure in kilopascals

Baseline, 3 months
Change in tongue muscle endurance as measured by time in seconds sustained at 50% maximal pressure.
Time Frame: Baseline, 3 months

Time in seconds sustained at 50% maximal pressure.

Baseline, 3 months
Change in Apnea-Hypopnea Index (AHI)
Time Frame: Baseline, 3 months

The apnea-hypopnea index (AHI) is the average number of breathing pauses (apneas) and shallow breathing events (hypopneas) that occur per hour of sleep, with higher scores indicating greater sleep apnea severity.

Baseline, 3 months
Change in Maximum Expiratory Pressure (MEP)
Time Frame: Baseline, 3 months

MEP is the highest positive pressure generated by a person during a forced exhalation against a blocked airway. It measures the strength of the expiratory muscles, including the abdominal and internal intercostal muscles, and helps evaluate cough efficiency and neuromuscular function. Lower scores indicate generalized respiratory muscle weakness, chronic obstructive pulmonary disease (COPD), or neuromuscular conditions like myasthenia gravis or Guillain-Barré syndrome.

Baseline, 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Thomaz Fleury Curado, MD, University Hospitals Cleveland Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY20261102

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.